IMR Press / FBL / Volume 11 / Issue 3 / DOI: 10.2741/1946

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Intravesical N-(4-hydroxyphenyl) retinamide and adriamycin induces apoptosis in bladder cancer
Show Less
1 Department of Urology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, China
2 Department of Urology, the Third Affiliated Hospital, Suzhou University, Changzhou, China
3 The Key Laboratory of Reproductive Medicine, Nanjing Medical University
4 Department of OB/GYN the University of Arizona, Tucson, AZ 85724
Academic Editor:Changping Zou
Front. Biosci. (Landmark Ed) 2006, 11(3), 2045–2051;
Published: 1 September 2006
(This article belongs to the Special Issue Cancer chemoprevention - 1)

The objective of this study was to evaluate the intravesical application of N-(4-hydroxyphenyl) retinamide (4-HPR) and adriamycin (ADM), as a treatment modality in a an animal model of chemically-induced bladder cancer. Bladder cancer developed in 50.0% of female Wistar rats, 4-6 weeks after intravesical application of the chemical carcinogen, N-methyl-N-nitrosourea (MNU). There was no significant difference in side effects induced by local versus systemic 4-HPR. Although tumor growth was inhibited by 4-HPR and ADM alone, tumor size was lower when both agents were used together. Apoptosis occurred at a higher rate in the combination group than when 4-HPR or ADM was used alone. The results suggest that intravesical use of 4-HPR and ADM may increase their efficacy in treatment of bladder cancer.

Urinary tract
Back to top